26 results about "Cells heart" patented technology

Provided herein are methods of preparing an engineered heart valve for implantation into a subject in need (e.g., a pediatric patient). For example, a porcine pulmonary valve can be decellularized and then recellularized with cells from the subject. Hydrogels can be used to facilitate cell delivery and growth within the sub-endothelial layer (e.g., spongiosa) of a heart valve, which is essential for long-term success of the implantation.

A heart organoid of at least 60% cardiac cells irrespective of optional additional cells of a vascular system of the organoid, or including at least 50% cardiac cells; wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from the group of cardiomyocytes, endocardial cells and epicardial cells, and wherein the heart organoid includes cardiomyocytes or endocardial cells that directly face the inner cavity, a method for the generation of such a tissue model and uses thereof.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein identified using a high-throughput sequencing screen or rational design. In particular, the disclosure provides AAV5 virions and capsid proteins with increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.

This disclosure relates generally to methods of screening and preparing cardiac cell therapies for potency (e.g., cardiac cell function).

The present disclosure describes ultrasound-based methods for facilitating the selective transduction of cardiac cells with therapeutic AAV vectors in vivo.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) generating receptor or a functional fragment thereof are provided. Expression vectors comprising the molecules, fusion proteins encoded by the molecules, cells, kits and pharmaceutical compositions are also provided. Methods of hyperpolarizing a cell, depolarizing a cardiac cell and treating a disease or condition are also provided.

The invention discloses a plant composition capable of efficiently activating anti-hypoxia activity of cardiac cells and a preparation method thereof.The preparation method comprises the steps that cardamine violifolia and rhodiola rosea are smashed and then mixed and pulped, water is added, pectinase, cellulase and hemicellulase are added for ultrasonic enzymolysis after high-pressure homogenization, centrifugal separation is performed, and a mixture is obtained; and after filtering, freezing and drying the supernate to obtain a mixed extract of cardamine violifolia and rhodiola rosea. According to the method, plant cell walls are crushed firstly through ultrahigh pressure extraction, functional components in cells are released, the functional components are dissolved in an extracting solution to the maximum extent under the action of enzymolysis and ultrasound, meanwhile, it can be guaranteed that chemical bonds of the functional components are not damaged, and the structural integrity and biological activity of the functional components are reserved to the maximum extent. The cardamine violifolia and the rhodiola rosea in the mixed extract have a synergistic effect, so that the taste of the product can be improved and the purpose of reducing the cost can be achieved under the condition that the use amount and the use period of the rhodiola rosea can be reduced.

The present invention discloses an application of an artificially designed novel NRG-1 in disease treatment. The present invention provides a nucleic acid molecule, an NRG1 protein variant, a vector, a vaccine, a cell, a pharmaceutical composition and a protein composition. The present invention also provides the following methods: a method for producing a protein, a method for producing a primary RNA polynucleotide. The present invention also provides the following applications: application in preparing a product for preventing, alleviating or treating cardiovascular diseases, application in preparing a product for preventing, alleviating or treating neurological diseases, application in preparing a product for maintaining the normal function of cardiac cells or tissues, and application in preparing a vaccine.

Methods and systems for cardiomyocyte maturation are generally described. In some embodiments, immature cardiomyocytes may be incubated with a three-dimensional matrix in an incubation medium and permitted to mature over a period of several weeks. In some embodiments, the three-dimensional matrix may include at least one population of microcarriers. The systems for cardiomyocyte maturation are evaluated for their scalability to meet large-scale global demand for cardiac cell therapies.

The present application relates to a novel micropeptide MP29 and a use thereof and relates to a use of the micropeptide in the preparation of a reagent or drug for preventing, treating, or alleviating diseases related to abnormal mitochondrial energy metabolism in cells, wherein the diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, aging, photoaging, fatty liver disease, liver fibrosis, liver cirrhosis, liver cancer, diabetic nephropathy, cardiovascular diseases such as heart failure, etc. By means of endogenous overexpression or exogenous synthesis, the reducing equivalents NADH in the tricarboxylic acid cycle are up-regulated to promote intracellular ATP production, thereby significantly enhancing the proliferation of high-energy-demanding cardiac cells and brain tissue cells, or suppressing oxidative damage and apoptosis of cells in Alzheimer's disease models and Parkinsonism, or alleviating hypertrophy and aging of myocardial cells in heart failure models, or ameliorating the photodamage of cells in photoaging models. These results indicate that the micropeptide MP29 has an application value in preventing or treating diseases related to abnormal mitochondrial energy metabolism.

This disclosure provides methods to modulate cardiac regeneration in a mammalian cardiac cell or progenitor, comprising contacting the mammalian cardiac cell with a DOT1L gene modulator.

Provided herein are composition and methods for gene therapy of LEM domain-containing protein 2 (LEMD2) cardiomyopathy. Viral vectors are used to deliver LEMD2 reading frame for gene augmentation in cardiac cells that harbor loss-of-function LEMD2 mutations. A murine model for LEMD2 cardiomyopathy is also described.

This disclosure relates generally to methods of screening and preparing high purity cardiac cell therapies and related cell preparations.

The invention relates to a differentiation culture method for cardiovascular organs, which comprises the following steps: using stem cells as starting cells, respectively carrying out seven-day cardiac cell induced differentiation culture and seven-day blood vessel induced differentiation culture, mixing, carrying out fusion culture, culturing for four days, carrying out dynamic culture from eleventh day to twentieth day, and harvesting the cardiovascular organs. Deepened vascularization can be seen in the central region of the organ. Compared with the prior art, the heart-like organ and the blood vessel-like organ are combined, various heart cell types and blood vessel cell types are included, and the implementation time is shorter. Through verification, the cardiovascular organoid model with improved maturity is obtained, the central area of the obtained cardiovascular organoid has a vascularization effect of penetration growth, and multiple culture and construction prove that the cardiovascular organoid model has stability and repeatability.

A medical tool testing apparatus comprising a vessel. The vessel comprises a scaffold formed from biomaterial, live cardiac tissue, generated from cardiac cells, proliferating on the scaffold, the live cardiac tissue configured to generate electrical activity. The vessel also comprises a medical tool, in contact with live cardiac tissue, used for a medical procedure within patient anatomy. Operational features of the medical tool are determined by a visually perceptible condition of the live cardiac tissue.

This disclosure relates generally to methods of screening and preparing high purity cardiac cell therapies and related cell preparations.

A platform with unique integrated electronic detection format to enable measurement of cell responses to chemical and physical stimulation on both sides of a porous membrane is disclosed. This sensing platform supports measurements including impedance measurements to determine physical displacement of cells and bioelectrical activity detection of cell-cell chemical induced responses in cardiomyocytes. Advantageously, cardiac cells can be positioned on opposite sides of a porous membrane and can be independently stimulated and monitored. Additionally, cardiac cells or other electrically active cells can be positioned and monitored on one side of the porous membrane, while other cells such as endothelial cells, epithelial cells, or liver cells may be positioned and monitored on the other side of the porous membrane.

The invention relates to compositions comprising cardiomyocytes, endothelial cells and fibroblasts, which are useful for studying cardiac biology and cardiotoxicity in vitro The invention also relates to cardiac spheroids obtained or obtainable from the compositions described herein, and their use in methods of drug screening and assessing cardiotoxicity.

The present invention provides a heart tissue model of at least 60% cardiac cells, wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from cardiomyocytes, endocardial cells and epicardial cells; method for the generation of such a tissue model and uses thereof.

This invention discloses a method for extracting interstitial fluid from cardiac tissue, belonging to the field of biomedical technology. Based on the unique characteristics of the heart, a organ closely related to blood circulation, and its differences in tissue physical properties compared to other organs, this invention designs and develops this extraction method, which specifically includes: rinsing isolated cardiac tissue with pre-cooled physiological saline; low-speed centrifugation to remove residual rinsing fluid from the heart; and centrifugation again to obtain interstitial fluid from the cardiac tissue. Comparison of the obtained interstitial fluid with cardiac cell fluid and serum confirms the accuracy and specificity of the extraction scheme of this invention. The centrifugation process of this invention does not damage cells, preserving its unique differences from serum and cardiac cell fluid. The extracted interstitial fluid has a high protein concentration, which can better reflect changes in the cardiac microenvironment, facilitating subsequent related medical and basic research.

A method of increasing sodium current in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription, thereby increasing sodium current in the cardiac cell. A method of increasing translation of SCN5A mRNA in a cell generally includes introducing into the cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of decreasing arrythmia in a cardiac cell generally includes introducing into the cardiac cell an miR-448 inhibitor in an amount effective to decrease miR-448 suppression of SCN5A mRNA transcription. A method of treating arrythmia in a patient having, or at risk of having, arrythmia generally includes administering to the patient an miR-448 inhibitor in an amount effective to decrease the likelihood or extent of arrythmia in the patient. In some embodiments of all methods, the miR-448 inhibitor can be an miR-448 antagomir or an miR-448 sponge.